EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Advances in T-Cell–Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies

Jinchul Kim, Seok Jin Kim

Cancer Research and Treatment · 15.10.2025 · 57 (4) · 905-922

DOI: 10.4143/crt.2025.440 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2025. Verfasst von Jinchul Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunotherapy, Adoptive, Lymphoma, B-Cell, T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell lymphomas are a heterogeneous group of malignancies with a high relapse rate after conventional therapies. T-cell–mediated immunotherapies, notably chimeric antigen receptor (CAR) T-cell therapies and T-cell–engaging bispecific antibodies (BsAbs), have transformed treatment paradigms by harnessing the immune system to target malignant cells. This review analyzes the efficacy and safety profiles of several CD19-targeted CAR T-cell therapies and emerging CD20×CD3 BsAbs across various B-cell lymphoma subtypes. While these therapies have demonstrated high response rates and potential for durable remissions, challenges such as cytokine release syndrome, neurotoxicity, and infections remain significant. Understanding these mechanisms and managing adverse effects are crucial for optimizing clinical outcomes and guiding future research in personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunotherapy, AdoptiveLymphoma, B-CellT-LymphocytesReceptors, Chimeric AntigenHumansAdultAntigens, CD19

Stichwörter der Autor:innen

B-cell lymphomasBispecific antibodyCAR T-cells

Substanzen

Antibodies, BispecificReceptors, Chimeric AntigenAntigens, CD19

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.

Förderung

  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare
  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Ministry of Trade, Industry and Energy

Zitieren

APA

Kim, J., & Kim, S. J. (2025). Advances in T-Cell–Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies. Cancer Research and Treatment, 57(4), 905-922. https://doi.org/10.4143/crt.2025.440

Vancouver

Kim J, Kim SJ. Advances in T-Cell–Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies. Cancer Research and Treatment. 2025;57(4):905-922. doi:10.4143/crt.2025.440

BibTeX
@article{Kim2025,
  author = {Kim, Jinchul and Kim, Seok Jin},
  title = {Advances in T-Cell–Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies},
  journal = {Cancer Research and Treatment},
  year = {2025},
  volume = {57},
  number = {4},
  pages = {905--922},
  doi = {10.4143/crt.2025.440}
}
Kostenlos starten →